Addex Therapeutics

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant (mGlu5 NAM) for post-stroke / TBI recovery, ADX71149 (mGlu2 PAM), and GABAB PAM candidates for substance use disorder and chronic cough. The company is described as a Swiss public company, with offices in Geneva, Switzerland and a US mailing address in Laguna Beach, California.

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. The company is described as a Swiss public company. Its contact information lists ADDEX THERAPEUTICS LTD and ADDEX PHARMA SA at Chemin des Mines, 9, CH-1202 Geneva, Switzerland, with a US mailing address for Addex Pharmaceuticals Inc. in Laguna Beach, California, and a registered office at Chemin Des Aulx 12, Case Postale 68, 1228 Plan-Les-Ouates, Switzerland. Its pipeline includes Dipraglurant (mGlu5 NAM) for post-stroke / TBI recovery, ADX71149 (mGlu2 PAM), and GABAB PAM candidates for substance use disorder and chronic cough. The company also references a spin-out company, Neurosterix, working on NTX-253 for schizophrenia.

Clinical-stage pharmaceutical company focused on allosteric modulators for neurological disorders.

• Dipraglurant (mGlu5 NAM)

  Pipeline candidate for post-stroke / TBI recovery.

• ADX71149 (mGlu2 PAM)

  Pipeline candidate.

• GABAB PAM - Substance Use Disorder

  Pipeline candidate for substance use disorder.

• GABAB PAM - Chronic Cough

  Pipeline candidate for chronic cough.

• Unconfirmed

  Addex appoints Darryle D. Schoepp to chair its scientific advisory board[6]Addex任命Darryle D. Schoepp担任科学顾问委员会主席finanznachrichten.de

  Reported: 2020-05-20

  Addex reported that it appointed Darryle D. Schoepp as chair of its newly formed scientific advisory board. The source does not give the appointment date.

• 2020-05-20

  Addex Therapeutics reports first-quarter 2020 results[6]Addex任命Darryle D. Schoepp担任科学顾问委员会主席finanznachrichten.de

  Reported: 2020-05-20

  Addex Therapeutics reported first-quarter 2020 financial results for the period ended March 31, 2020, including a net loss of CHF 4.306 million and cash and cash equivalents of CHF 27.126 million.

1. 1Addex therapeutics :: ENaddexpharma.com
2. 2Addex therapeutics :: About usaddexpharma.com
3. 3Addex therapeutics :: Contactaddexpharma.com
4. 4Addex therapeutics :: Careersaddexpharma.com
5. 5Addex Therapeuticswikidata.org
6. 6Addex任命Darryle D. Schoepp担任科学顾问委员会主席finanznachrichten.de
7. 7Addex Reports Q3 2020 Financial Results and Provides Corporate Updatefinance.yahoo.com